PMID: 8946657Dec 1, 1996Paper

Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol

Therapeutic Drug Monitoring
K Linnet, O Wiborg

Abstract

One hundred and nineteen psychiatric patients undergoing therapeutic drug monitoring (TDM) of the neuroleptic zuclopenthixol were genotyped with regard to Cyp2D6. Twelve patients (10.1%) were of the poor metabolizer genotype. The extensive metabolizers comprised 58 patients receiving no potentially interacting drugs and 38 patients concomitantly treated with other drugs competing for metabolism by Cyp2D6. Information on the rest (11 patients) was missing. The median steady-state serum concentration-to-dose ratio (C/D) of the PM group (2.00 nmol/L/mg) was close to that of the EM group receiving potentially interacting drugs (1.80) and approximately 60% higher than that of the remaining EM group (1.25) (p < 0.01). When judging the clinical importance of this difference, the total group variability in C/D of nearly 10-fold should be kept in mind (0.5-4.2 nmol/L/mg). In terms of serum concentrations not corrected for dose, the three groups had about similar levels, with median values from 16 to 21 nmol/L. We consider that TDM adequately takes into account dose adjustments for both EM and PM subjects in the context of this neuroleptic.

References

Apr 1, 1992·Therapeutic Drug Monitoring·A LlerenaL Bertilsson
Jan 1, 1991·Methods in Enzymology·N K SpurrC R Wolf
Mar 1, 1991·Clinical Pharmacology and Therapeutics·C von BahrF Sjöqvist
Jan 1, 1990·European Journal of Clinical Pharmacology·J W MeyerU A Meyer
Jan 1, 1990·European Journal of Clinical Pharmacology·G AlvánU Gundert-Remy
Jul 1, 1989·Clinical Pharmacology and Therapeutics·M L Dahl-PuustinenL Bertilsson
Jun 1, 1995·Journal of Clinical Psychopharmacology·H ArthurF Sjöqvist
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·I JohanssonM Ingelman-Sundberg
Apr 1, 1993·Pharmacogenetics·M L Dahl, L Bertilsson

❮ Previous
Next ❯

Citations

Oct 13, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Feb 20, 2002·British Journal of Clinical Pharmacology·Leif BertilssonAyman Al-Shurbaji
May 12, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Markéta BébarováJirí Simurda
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·D ZullinoP Baumann
Jul 23, 2013·Schizophrenia Research·Dana RavynHenry A Nasrallah
Sep 10, 2014·Journal of Neural Transmission·Edoardo Spina, Jose de Leon
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Feb 25, 2000·Therapeutic Drug Monitoring·K Otani, T Aoshima
Oct 30, 2020·British Journal of Clinical Pharmacology·Ragnhild Birkeland WaadeGudrun Høiseth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here